BTK Inhibitors Crossing the Blood-Brain Barrier: Conflicting Clinical Evaluations on Inhibiting Multiple Sclerosis Progression

Background
Multiple Sclerosis (MS) is a chronic autoimmune disease where the immune system attacks the myelin in the central nervous system (CNS), causing nerve damage. The existing treatment landscape has been dominated by B-cell depletion therapies, such as anti-CD20 monoclonal antibodies like ocrelizumab. These therapies have achieved remarkable success in reducing acute inflammation and relapse frequency by targeting B cells in the peripheral blood.
However, antibody therapies, which are large protein structures, have a blood-brain barrier (BBB) permeability of less than 0.1%. Consequently, they were insufficient to control the chronic compartmentalized inflammation and microglial activation occurring within the brain parenchyma. This highlights a persistent limitation: the inability to halt disease progression independent of relapse activity (PIRA), wherein neurodegeneration and disability accumulate silently even in the absence of relapse symptoms. Accordingly, Bruton's tyrosine kinase (BTK) inhibitors have emerged as a new oral therapeutic target for directly penetrating the CNS to simultaneously control both adaptive and innate immune pathways.
Key Findings
BTK inhibitors not only inhibit the B-cell receptor (BCR) signaling pathway that induces B-cell maturation and activation but also simultaneously inhibit the Fc receptor signaling system of macrophages and microglia within the CNS. The key differentiator is their ability to control immune pathology in both the peripheral circulation and the brain parenchyma, based on the high BBB permeability characteristic of small molecule compounds.
A review paper recently published in The Lancet analyzed the practical utility of this class of drugs by synthesizing clinical results of major drugs, including evobrutinib, tolebrutinib, and fenebrutinib.
Clinical data revealed starkly divergent outcomes depending on the disease type. In the context of relapsing-remitting multiple sclerosis (RRMS), characterized by predominant relapses, BTK inhibitors failed to significantly reduce the annualized relapse rate (ARR) compared with teriflunomide, an established first-line therapy. Both the Evolution phase 3 clinical trial of evobrutinib and the GEMINI 1·2 studies of tolebrutinib failed to reach the primary endpoint of reducing relapse rates. The results did not demonstrate superiority over existing anti-CD20 antibodies in terms of acute relapse suppression.
In contrast, the HERCULES phase 3 clinical trial of tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS) yielded encouraging results. It met the primary endpoint by reducing the risk of 6-month confirmed disability accumulation (CDA) by 31% compared to the placebo group. This is a significant indicator demonstrating that alleviating neuroinflammation through microglia inhibition can contribute to the preservation of physical function in patients with progressive conditions.
Implications and Outlook
These evaluation results show the need to redefine the position of BTK inhibitors in the treatment of multiple sclerosis. In the treatment of early-stage patients with a focus on relapse suppression, existing high-efficacy B-cell-depleting antibodies are likely to maintain a firm position. Conversely, for the non-relapsing progressive patient group, which lacked adequate treatment options, BTK inhibitors that directly target compartmentalized inflammation in the CNS are emerging as a new alternative.
However, challenges to overcome for integration into clinical practice are clear. There are variations in efficacy between drugs depending on whether the binding is reversible or irreversible, and the risk of hepatotoxicity, such as increased liver enzyme levels, requires continuous monitoring. Follow-up studies are essential to determine whether BBB permeability actually leads to long-term inhibition of neural damage and delayed reduction in brain volume. As data from phase 3 studies of fenebrutinib, which employs a reversible non-covalent binding mechanism, accumulate, the precise clinical role of this class of therapeutics is expected to be established.
Bruton's tyrosine kinase (BTK) inhibitors directly modulate the functions of B lymphocytes and myeloid cells (notably macrophages and microglia) and thus target both the adaptive and innate mechanisms that contribute to the immunopathology of multiple sclerosis on either side of the blood–brain barrier. Treatment with BTK inhibitors capable of crossing the CNS could slow the progression of the disease by targeting immune cells on both sides of the blood–brain barrier.1 Although the results of clinical trials have been published for at least three BTK inhibitors (evobrutinib,2 tolebrutinib,3 and fenebrutinib4), the actual impact of this newer class of drugs on the treatment strategy for relapsing and progressive multiple sclerosis remains a subject of debate.
This study provides clear patient selection criteria for the treatment of progressive multiple sclerosis, a condition with a high unmet need. Rather than applying BTK inhibitors to all MS patients, clinicians can adopt a precision approach by selecting and prescribing to non-relapsing secondary progressive patients whose disability progresses regardless of relapse.
In terms of the pharmaceutical industry, it serves as a direct compass for discovery strategies for next-generation BTK inhibitors with improved CNS permeability and safety. It is expected that the development of combination therapy scenarios, such as combining or sequentially administering existing peripheral B-cell targeting antibodies and brain-penetrating BTK inhibitors, will gain momentum.